The Commission may challenge Grifols SA planned purchase of Talecris Biotherapeutics “on fears the merger would reduce supplies and raise prices for medicines to treat a range of autoimmune disorders,” according...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: